This Article Full Text Full Text (PDF) All Versions of this Article: 1055-9965.EPI-07-0448v1 16/11/2213    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jacobs, E. J. Articles by Calle, E. E. Search for Related Content PubMed PubMed Citation Articles by Jacobs, E. J. Articles by Calle, E. E. Related Collections Commentary

Cholesterol-Lowering Drugs and Advanced Prostate Cancer Incidence in a Large U.S. Cohort

Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, Georgia

Requests for reprints: Eric J. Jacobs, Epidemiology and Surveillance Research, American Cancer Society, National Home Office, 250 Williams Street, Atlanta, GA 30303-1002. Phone: 404-329-7916; Fax: 404-327-6450. E-mail: Eric.Jacobs{at}cancer.org

Background: 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors, commonly known as statins, account for the great majority of cholesterol-lowering drug use in the United States. Long-duration statin use was associated with substantially reduced risk of advanced prostate cancer in a recent large prospective study.

Methods: We examined the association between use of cholesterol-lowering drugs and prostate cancer incidence by disease stage and grade among 55,454 men in the Cancer Prevention Study II Nutrition Cohort. Proportional hazards modeling was used to calculate RRs.

Results: During follow-up from 1997 to 2003, we identified 3,413 cases of incident prostate cancer, including 317 cases of advanced prostate cancer. After adjustment for age, history of prostate-specific antigen testing, and other potential prostate cancer risk factors, current use of cholesterol-lowering drugs for 5 or more years was not associated with overall prostate cancer incidence (multivariate adjusted rate ratio, 1.06; 95% confidence interval, 0.93-1.20), but was associated with a marginally statistically significant reduction in risk of advanced prostate cancer (rate ratio, 0.60; 95% confidence interval, 0.36-1.00).

Conclusion: These results provide some support for the hypothesis that long-term statin use is associated with reduced risk of advanced prostate cancer. (Cancer Epidemiol Biomarkers Prev 2007;16(11):2213–7)

Commentary

Epidemiologic Musing on Statin Drugs in the Prevention of Advanced Prostate Cancer

Elizabeth A. Platz
Cancer Epidemiol. Biomarkers Prev. 2007 16: 2175-2180. [Full Text] [PDF]

This article has been cited by other articles:

				I. Agalliu, C. A. Salinas, P. D. Hansten, E. A. Ostrander, and J. L. Stanford Statin Use and Risk of Prostate Cancer: Results from a Population-based Epidemiologic Study Am. J. Epidemiol., August 1, 2008; 168(3): 250 - 260. [Abstract] [Full Text] [PDF]

				E. A. Platz Epidemiologic Musing on Statin Drugs in the Prevention of Advanced Prostate Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2175 - 2180. [Full Text] [PDF]